Akeso, Inc. (HKG:9926)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 75.71B |
| Revenue (ttm) | 2.26B |
| Net Income (ttm) | -547.53M |
| Shares Out | 897.58M |
| EPS (ttm) | -0.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,144,619 |
| Average Volume | 17,066,027 |
| Open | 84.25 |
| Previous Close | 84.25 |
| Day's Range | 83.60 - 85.20 |
| 52-Week Range | 26.45 - 105.50 |
| Beta | 0.60 |
| RSI | 51.31 |
| Earnings Date | May 28, 2025 |
About Akeso
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell carcinoma, breast cancer, colorectal cancer, and pancreatic cancer. It is also developing AK117, a CD47 monoclonal antibody to treat myelodyspl... [Read more]
News
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Summit Therapeutics Inc. (NASDAQ: SMMT) on Friday noted that Akeso, Inc. announced the Chinese Health Authorities, the National Medical Products Administration (NMPA) approved ivonescimab for a secon...
China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug
Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase three trial.
What's Going On With Summit Therapeutics Stock On Friday?
Summit Therapeutics Inc (NASDAQ: SMMT) stock is trading lower on Friday. On Thursday, Summit Therapeutics’ partner Akeso Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-...
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit Therapeutics Inc.'s (NASDAQ: SMMT) partner, Akeso, Inc. , released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday. The trial is evaluating ivonescimab in combination with ...
Akeso (9926) Poised for Growth Despite Current Undervaluation
Akeso (9926) Poised for Growth Despite Current Undervaluation
Bullish On Akeso's Ivonescimab, But Valuation And Geopolitical Risks Remain
Why This Chinese Biotech Could Be Pharma's DeepSeek
The drugmaker's shares rallied after the release of its strong annual report, up by a cumulative 18% over the next three trading days Key Takeaways: Akeso's drug sales rose 25% last year to just above...
Akeso reports FY results
Chinese drug maker Akeso hailed as biotech's 'DeepSeek moment' amid US competition
Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed as the "DeepSeek moment" for China's drug industry, as biotech emerges as a...
Chinese drug maker Akeso hailed as biotech’s ‘DeepSeek moment’ amid US competition
Akeso’s immunotherapy drug allowed half of its patients to go 11.1 months without their condition worsening.
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE (NASDAQ: BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical development across multiple solid tumors. Data from Summit Therapeutics Inc . ...
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ: SMMT), noting the company’s initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed...